| Texto completo | |
| Autor(es): |
Wagner, Vivian Petersen
;
Ferrarotto, Renata
;
Vargas, Pablo Agustin
;
Martins, Manoela Domingues
;
Bingle, Colin D.
;
Bingle, Lynne
Número total de Autores: 6
|
| Tipo de documento: | Artigo Científico |
| Fonte: | CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY; v. 181, p. 12-pg., 2023-01-01. |
| Resumo | |
Adenoid cystic carcinoma (ACC) has a significant patient-population in need of effective systemic therapy, as no drug is currently approved by the FDA for its management. We critically reviewed ACC-clinical trials (CT) registered on the ClinicalTrials.gov website using "ACC" under condition or disease. Trials specifically designed to test a drug-based therapy for ACC (n = 33) were analyzed with most being one-arm phase II trials enrolling advanced, recurrent/metastatic, incurable ACC cases. Site restriction, maximum ECOG status, and period of disease progression varied as inclusion criteria. Small-molecule inhibitors were those most commonly investi-gated with Apatinib, Axitinib and Lenvatinib showing the best results in association with rigid enrollment criteria. The overall median time to progression remains modest and more efforts are urgently needed in this field. CTs designed to test drugs that act on key pathways associated with ACC aggressiveness are being con-ducted and represent a promising pathway if efficacy is proved. (AU) | |
| Processo FAPESP: | 16/05710-4 - Disrupção da resistência tumoral através de terapia direcionada a depleção de células tronco tumorais em carcinomas espinocelulares de cabeça e pescoço |
| Beneficiário: | Pablo Agustin Vargas |
| Modalidade de apoio: | Auxílio à Pesquisa - Temático |